Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation (NYSE: SYK) is described as a global leader in medical technologies, with a focus on MedSurg, Neurotechnology and Orthopaedics. The news flow around Stryker reflects this broad footprint, covering topics from product launches and clinical technology updates to quarterly financial results, leadership changes and portfolio transactions.
Investors following SYK news will see regular announcements of earnings results, including detailed third quarter and other period operating updates furnished via press releases and Form 8-K filings. These communications typically discuss segment performance in MedSurg and Neurotechnology and Orthopaedics, along with commentary from management on sales trends and margins.
Stryker also issues news about product innovation in orthopaedics and trauma. Recent examples include the launch of the FDA-cleared Incompass Total Ankle System for patients with end-stage ankle arthritis and updates on trauma offerings such as the Pangea platform and T2 Alpha system, which are designed to support complex fracture management. These announcements often coincide with major medical society meetings and highlight design goals and clinical use cases.
Corporate and strategic developments appear frequently in Stryker’s news stream. The company has reported leadership changes, such as the appointment of a President and Chief Operating Officer and the promotion of a new Group President, Orthopaedics. It has also communicated portfolio moves, including references to the divestiture of its spinal implant business and news that VB Spine LLC acquired Stryker’s U.S. spine implant business and a spine implant manufacturing facility in Cestas, France.
In addition, Stryker announces investor events, such as upcoming earnings webcasts, participation in healthcare conferences and Investor Day presentations. For investors and healthcare professionals, the SYK news page provides a centralized view of these financial, strategic and product-related updates, offering context on how the company’s medical technologies and corporate decisions evolve over time.
Stryker (NYSE:SYK) will host a conference call on October 29, 2020, at 4:30 p.m. ET to discuss its Q3 2020 operating results and provide an operational update. The final results will be released at 4:05 p.m. ET on the same day. Interested participants can join the call by dialing (877) 702-4565 for domestic calls or (647) 689-5532 for international calls, using conference ID 5297589. A webcast will be available on Stryker's website, which will also host archived recordings of the call from October 29, 2020, 8:00 p.m. ET until November 5, 2020, 11:59 p.m. ET.
Stryker (NYSE:SYK) will host a conference call on October 29, 2020, at 4:30 p.m. ET, to discuss its operating results for the quarter ended September 30, 2020. The final results will be released at 4:05 p.m. on the same day. To join the call, dial (877) 702-4565 domestically or (647) 689-5532 internationally, using conference ID 5297589. A webcast will be available on their website, and the call will be archived for later access until November 5, 2020.
Stryker (NYSE: SYK) will participate in the Morgan Stanley 18th Annual Virtual Global Healthcare Conference on September 15, 2020, at 10:15 a.m. Eastern Time. Kevin Lobo, the Chairman and CEO, will represent the company. A webcast and replay of the presentation will be accessible on Stryker's website, www.stryker.com, and archived on the Investor Relations page. Stryker is a leader in medical technology, focusing on improving healthcare through innovative products in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Stryker (NYSE: SYK) has extended the cash tender offer for Wright Medical Group N.V. (NASDAQ: WMGI) shares, now set to expire on September 30, 2020. As of August 27, 2020, approximately 10.5% of Wright Medical's ordinary shares were validly tendered. The tender offer's completion is contingent on certain conditions outlined in Stryker's filings with the SEC. Shareholders who have already tendered their shares do not need to take further action due to this extension. Innisfree M&A Incorporated serves as the information agent for the tender offer, with contact information provided.
Stryker reported a significant net sales decrease of 24.3% for Q2 2020, totaling $2.8 billion, attributable to COVID-19 impacts, including postponed medical procedures. Adjusted EPS fell 67.7% to $0.64, while reported EPS decreased by 117.5% to ($0.22). All business segments, including Orthopaedics and MedSurg, faced declines. The company projects continued negative effects from the pandemic, limiting financial outlook and guidance.
Stryker (NYSE: SYK) has declared a quarterly dividend of $0.575 per share, payable on October 30, 2020, to shareholders on record as of September 30, 2020. This dividend represents an increase of approximately 11% compared to the previous year, although it remains unchanged from the last quarter. Stryker continues to lead in the medical technology sector, offering innovative solutions across Orthopaedics, Medical and Surgical, and Neurotechnology and Spine, aimed at improving patient and hospital outcomes.
Stryker (NYSE: SYK) will host a conference call on July 30, 2020, at 4:30 p.m. ET to discuss its operating results for the quarter ending June 30, 2020. The final results will be released earlier that day at 4:05 p.m. ET. Interested parties can join the call by dialing (877) 702-4565 domestically or (647) 689-5532 internationally, and must provide conference ID 1335868. A webcast will be available on Stryker's website, with a recording accessible from 8:00 p.m. ET on July 30 until August 7, 2020.
Stryker has priced its offering of senior notes, raising a total of $2.3 billion through three series: $650 million of 1.150% Notes due 2025, $1 billion of 1.950% Notes due 2030, and $650 million of 2.900% Notes due 2050. Proceeds will primarily fund the acquisition of Wright Medical Group, along with fees and general corporate purposes. The offering is expected to close on June 4, 2020. Various risks, including regulatory hurdles and economic factors, could impact the acquisition and future performance.
Summary not available.
Summary not available.